Clinical trial
A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In…
NCT00391196 · Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00391196 |
|---|---|
| Title | A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients |
| Official title | A 1-Year, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study To Evaluate The Efficacy And Safety Of CP-945,598 In The Treatment Of Overweight, Oral Agent-Treated Subjects With Type 2 Diabetes Mellitus |
| Lead sponsor | Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Obesity |
| Intervention type | Drug |
| Interventions | Placebo, CP-945, 598, 598 Treatment B |
| Enrollment | 975 |
| Start date | Nov 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Jan 1, 2009 |
| First posted | Oct 23, 2006 |
| Last update posted | Nov 7, 2012 |
| Countries | Argentina, Australia, Brazil, Canada, Czechia, Germany, Mexico, Slovakia, Sweden, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: